Acute Lymphoblastic Leukemia
New research confirms that gut microbiome dysbiosis is present in survivors of childhood acute lymphoblastic leukemia.
Charles G. Mullighan, MBBS (Hons), MSc, MD, discusses the latest research out of St Jude at ASH 2018.
With newer treatments, alternatives to dasatinib exist, if needed.
High levels of CAR-T cell expansion in vivo and high pretreatment disease burden appeared to increase the likelihood that a neurotoxic event may occur following CAR-T administration.
The efficacy of nelarabine among newly diagnosed patients with T-cell ALL has not been fully explored.
The FDA based its approval on results of the single-arm phase 2 JULIET clinical trial.
Previous studies demonstrated that inotuzumab ozogamicin significantly improves clinical outcomes vs standard of care chemotherapy, but impact on QoL was unknown.
1. Patients with a higher disease burden of acute lymphoblastic leukemia (ALL) treated with CD19-specific chimeric antigen receptor (CAR) T cell therapy experienced greater incidences of cytotoxic release syndrome and neurotoxicity compared to low disease burden patients. 2. Patients with high disease burden had shorter overall survival times compared to low disease burden patients. Evidence 
Researchers evaluated the outcomes of older vs younger patients with R/R ALL treated with InO or investigators' choice of chemotherapy.
Inherited TP53 variants may be crucial for acute lymphoblastic leukemia (ALL) leukemogenesis and response to treatment, according to a study published in the Journal of Clinical Oncology.1
Researchers assessed the efficacy of dasatinib — a TKI that is significantly more potent than imatinib and is active even in the setting of imatinib resistance — in this patient population.
Based on findings from previous studies (COG AALL0031 and EsPhALL 2004-2009), researchers are assessing the association of continuous imatinib plus chemotherapy with the reduced need for HSCT.
Elias Jabbour, MD, discusses the latest developments in the treatment of acute and chronic leukemia from the ASH 2017 meeting.
Eleven patients had a complete response: 10 had complete cytogenic remission, 8 were negative by flow cytometry, 6 had undetectable BCR-ABL. Three patients did not respond.
For a meta-analysis, researchers evaluated outcomes data from 9 studies consisting of 6762 patients with an acute leukemia to determine whether HSCT is superior to UCBT.
Previous studies demonstrated that MRD and genetic abnormalities are critical predictors of relapse in ALL, but current algorithms view MRD and genetics as independent variables when assessing risk.
The FDA granted approval to inotuzumab ozogamicin for the treatment of adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Enthusiasm for the CAR T cell approach may redirect rather than augment other possibly safer, more effective, evolutionarily informed approaches to cancer therapy.
Early response-based treatment intensification with allo-SCT improved OS among adult patients with early thymic precursor T cell ALL.
Long-term cure of ALL is achieved by 80% of children with the disease, but questions remain regarding how to balance morbidity and HRQoL related to treatment.
Leukemia remains the most common cancer type for children aged 14 years or younger, worldwide, representing a third of cases for children younger than 10 years.
The addition of rituximab to chemotherapy may benefit patients being treated for acute lymphoblastic leukemia (ALL).
This fact sheet provides patients with acute lymphocytic leukemia strategies for coping, treatment options, and more.
Patients with ALL treated with the monoclonal antibody inotuzumab ozogamicin were more likely to proceed to stem cell transplantation.
Ponatinib resulted in durable responses after 4 years in heavily pretreated patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
Young children born by pre-labor cesarean delivery may be at an increased risk of childhood acute lymphoblastic leukemia (ALL).
Results of TOWER study evaluating blinatumomab in acute lymphoblastic leukemia (ALL) showed that the primary endpoint was met.
An intensive pediatric-like acute lymphoblastic leukemia (ALL) treatment protocol was associated with a good response rate.
Adding rituximab to the pediatric-inspired GRAALL protocol improved event-free survival in acute lymphoblastic leukemia.
The change in drug sensitivity by tumor cells resistant to Notch or BET inhibitors results from selective use of individual enhancers.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?